Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML

This phase I/II trial studies the side effects of laboratory-treated (central memory/naive) cluster of differentiation 8+ T cells (autologous Wilms tumor [WT]1-T cell receptor [TCRc]4 gene-transduced CD8-positive central memory T-cells [TCM]/naive T cells [TN] lymphocytes) and how well it works in treating patients with acute myeloid leukemia that is newly diagnosed or has come back. Genetically modified therapies, such as autologous WT1-TCRc4 gene-transduced CD8-positive TCM/TN lymphocytes, are taken from a patient's blood, modified in the laboratory so they specifically may kill cancer cells with a protein called WT1, and safely given back to the patient. The "genetically modified" T-cells have genes added in the laboratory to allow them to recognize leukemia cells that express WT1 and kill them.

开始日期2017-11-06

申办/合作机构

Fred Hutchinson Cancer Research Center

[+1]

NCT02408016

/ Terminated临床1/2期IIT

Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor

This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.

开始日期2015-05-22

申办/合作机构

Fred Hutchinson Cancer Research Center

[+1]

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的临床结果

登录后查看更多信息

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的转化医学

登录后查看更多信息

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性急性髓细胞白血病	临床2期	美国	Fred Hutchinson Cancer Research Center	2017-11-06
恶性胸膜间皮瘤	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22
转移性非小细胞肺癌	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22
非小细胞肺癌IIIA期	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22
非小细胞肺癌IIIB期	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22
复发性非小细胞肺癌	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22
肾母细胞瘤	临床2期	美国	Fred Hutchinson Cancer Research Center	2015-05-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02408016 (CTgov)	临床1/2期	非小细胞肺癌IIIA期 \| 恶性胸膜间皮瘤 \| 肾母细胞瘤 ... 更多	11	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Cyclophosphamide+Aldesleukin (Arm I, Stage I (T Lymphocytes, Cyclophosphamide, IL-2))	衊繭獵淵醖鹽糧齋襯獵 = 鑰夢鑰構鏇築簾願窪夢構艱築遞蓋鬱襯獵醖襯 (鹹廠遞鹹艱膚選製製鏇, 憲鬱網網膚鏇築醖壓齋 ~ 鹹顧鹽襯膚淵窪齋壓餘) 更多	-	2021-09-13
NCT02408016 (CTgov)	临床1/2期	非小细胞肺癌IIIA期 \| 恶性胸膜间皮瘤 \| 肾母细胞瘤 ... 更多	11	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Cyclophosphamide+Aldesleukin (Arm I, Stage II (T Lymphocytes, Cyclophosphamide, IL-2))	衊繭獵淵醖鹽糧齋襯獵 = 積鏇壓顧鹹廠淵顧淵簾構艱築遞蓋鬱襯獵醖襯 (鹹廠遞鹹艱膚選製製鏇, 衊醖製糧鬱襯製餘鑰壓 ~ 艱醖鑰蓋遞夢淵範鏇遞) 更多	-	2021-09-13
NCT02770820 (CTgov)	临床1/2期	复发性急性髓细胞白血病 \| 肾母细胞瘤	9	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Aldesleukin	淵膚簾製製鬱衊餘積艱 = 蓋繭繭選鬱醖夢艱製獵鹽膚襯糧繭鏇衊窪簾壓 (壓獵夢衊齋觸製選網鏇, 鑰衊壓獵糧願廠襯餘積 ~ 壓築獵鑰網築製夢鏇艱) 更多	-	2021-06-23